LUMO
NASDAQLumos Pharma Inc.
Latest news
25 items- PRAviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of DirectorsAviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car
- SECSEC Form 15-12G filed by Lumos Pharma Inc.15-12G - LUMOS PHARMA, INC. (0001126234) (Filer)
- INSIDERChief Executive Officer Hawkins Richard J returned 757,562 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERDirector Zoth Lota S. returned 2,187 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERChief Scientific Officer Mckew John C. returned 13,153 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERDirector Johnson Chad Allen returned 1,076 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERDirector Van Es-Johansson An returned 1,100 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERDirector Raffin Thomas A. returned 9,406 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERChief Medical Officer Pitukcheewanont Pisit Duke returned 16,836 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERDirector Lalande Kevin M. returned 731,522 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERChief Business Officer Schuchart Aaron returned 8,179 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERGeneral Counsel Powers Bradley J returned 6,334 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERDirector Mccracken Joseph S returned 15,721 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- INSIDERChief Financial Officer Lawley Lori D returned 12,284 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
- SECSEC Form AW filed by Lumos Pharma Inc.AW - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form EFFECT filed by Lumos Pharma Inc.EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form EFFECT filed by Lumos Pharma Inc.EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form EFFECT filed by Lumos Pharma Inc.EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form EFFECT filed by Lumos Pharma Inc.EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form EFFECT filed by Lumos Pharma Inc.EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form POS AM filed by Lumos Pharma Inc.POS AM - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form POS AM filed by Lumos Pharma Inc.POS AM - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form POS AM filed by Lumos Pharma Inc.POS AM - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form POS AM filed by Lumos Pharma Inc.POS AM - LUMOS PHARMA, INC. (0001126234) (Filer)
- SECSEC Form POS AM filed by Lumos Pharma Inc.POS AM - LUMOS PHARMA, INC. (0001126234) (Filer)
LUMO FAQ
7 questionsWhat does Lumos Pharma Inc. do?
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.Where does LUMO stock trade?
Lumos Pharma Inc. (LUMO) is listed on NASDAQ.What sector and industry is LUMO in?
Lumos Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lumos Pharma Inc. go public?
Lumos Pharma Inc. (LUMO) completed its IPO in 2011.What are analysts saying about LUMO?
Lumos Pharma Inc. has had 2 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $2800.00 price target on 2021-11-04. Recent price targets range from $2700.00 to $2800.00.What companies are similar to LUMO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LUMO side-by-side with any of them on Quantisnow.How can I track LUMO on Quantisnow?
Quantisnow aggregates Lumos Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LUMO to receive live email and push alerts on every new disclosure.